



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Celecoxib-d₇

Cat. No.:	HY-14398S		
CAS No.:	544686-21-7		
Molecular Formula:	C ₁₇ H ₇ D ₇ F ₃ N ₃ O ₂ S		
Molecular Weight:	388.42		
Target:	COX		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 76 mg/mL (195.66 mM)
 DMSO : ≥ 76 mg/mL (195.66 mM)
 Ethanol : ≥ 33 mg/mL (84.96 mM)
 Ethanol : ≥ 33 mg/mL (84.96 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		2.5745 mL	12.8727 mL	25.7453 mL
	5 mM		0.5149 mL	2.5745 mL	5.1491 mL
	10 mM		0.2575 mL	1.2873 mL	2.5745 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Celecoxib-d₇ is the deuterium labeled Celecoxib. Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC₅₀ of 40 nM^{[1][2]}.

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

-
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. *Acta Pharmacol Sin.* 2012 May;33(5):682-90.
- [3]. Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, celecoxib). *J Med Chem.* 1997
- [4]. Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. *Neural Regen Res.* 2015 Nov;10(11):1836-40.
- [5]. Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. *Oncotarget.* 2016 Apr 8.
- [6]. Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. *Theranostics.* 2020 Feb 18;10(8):3622-3635.
- [7]. Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. *Sci Rep.* 2018 Mar 7;8(1):4108.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA